Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
GSK, Amgen want SCOTUS to protect genus claims
18-11-2020
Vectura wins additional $10m patent damages against GSK
16-09-2019
The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s (GSK) challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, GlaxoSmithKline, Vectura, patent infringement, inhalers, Federal Circuit, Ellipta
